SequelSEC

TANDEM DIABETES CARE INC TNDM

Surgical & Medical Instruments & Apparatus · CIK 0001438133 · Fiscal year ends 1231

Revenue
$1.01B
Fiscal year ended 2025-12-31
Operating income
-$187.26M
Fiscal year ended 2025-12-31
Free cash flow
-$29.67M
Fiscal year ended 2025-12-31

TANDEM DIABETES CARE INC (TNDM) reported revenue of $1.01B and net income of -$204.71M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from TANDEM DIABETES CARE INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

TANDEM DIABETES CARE INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$1.01B$940.20M$747.72M$801.22M$702.80M$498.83M$362.30M$183.87M$107.60M$84.25M
Cost of revenue$468.72M$450.63M$380.03M$388.23M$326.58M$238.31M$168.09M$94.04M$63.51M$60.66M
Gross profit$546.01M$489.57M$367.69M$412.99M$376.22M$260.52M$194.21M$89.82M$44.09M$23.59M
Operating income-$187.26M-$99.13M-$233.23M-$92.85M$22.65M-$7.96M-$16.72M-$44.63M-$62.94M-$78.05M
Net income-$204.71M-$96.02M-$222.61M-$94.59M$15.57M-$34.38M-$24.75M-$122.61M-$73.03M-$83.45M
Research & developmentUnavailableUnavailableUnavailableUnavailable$92.05M$63.57M$45.20M$29.23M$20.66M$18.81M
Weighted-average diluted sharesshares 67.28Mshares 65.45Mshares 64.97Mshares 64.15Mshares 64.35Mshares 60.99Mshares 58.51MUnavailableUnavailableUnavailable
Pretax income-$200.27M-$91.87M-$220.25M-$92.85M$15.90M-$36.28M-$24.60M-$122.56M-$73.02M-$83.46M
Income tax expense$4.44M$4.16M$2.36M$1.74M$335.00K-$1.90M$149.00K$51.00K$8.00K-$15.00K
Diluted EPS$-3.04$-1.47$-3.43$-1.47$0.24$-0.56$-0.42UnavailableUnavailableUnavailable
Selling, general & administrative$444.99M$389.82M$352.50M$335.68M$261.51M$204.90M$165.74M$105.23M$86.38M$82.83M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

TANDEM DIABETES CARE INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Cash & equivalents$90.63M$69.23M$58.87M$172.52M$71.18M$94.61M$51.18M$41.83M$13.70M$44.68M
Total assets$881.11M$967.66M$952.66M$1.05B$905.14M$716.42M$326.11M$206.29M$95.35M$112.39M
Current assets$618.14M$724.49M$747.99M$849.98M$811.52M$637.24M$276.14M$187.88M$64.16M$92.09M
Total liabilities$725.94M$704.56M$639.03M$612.84M$472.02M$350.11M$131.13M$75.02M$124.49M$118.32M
Current liabilities$242.72M$247.05M$195.26M$165.29M$131.86M$103.85M$99.40M$66.29M$36.08M$31.48M
Total equity incl. NCI$155.17M$263.10M$313.63M$439.95M$433.11M$366.30M$194.98M$131.28M-$29.15M-$5.93M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$128.77M$149.61M$157.94M$111.12M$68.55M$63.72M$49.07M$19.90M$26.99M$21.20M
Accounts receivable$165.49M$114.58M$105.56M$114.72M$110.72M$82.20M$46.58M$35.19M$20.79M$11.17M
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$310.04M$308.27M$285.04MUnavailableUnavailableUnavailableUnavailableUnavailable$82.70M$81.08M
Accounts payable$47.07M$44.73M$49.59M$55.73M$28.03M$17.80M$17.74M$6.82M$5.15M$7.51M

Cash flow

TANDEM DIABETES CARE INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Operating cash flow-$9.72M$24.22M-$31.81M$50.46M$111.36M$24.67M$41.91M-$8.32M-$66.14M-$61.17M
Capital expenditures$19.95M$19.23M$26.80M$34.10M$14.18M$27.41M$19.54M$2.99M$5.72M$8.93M
Investing cash flow$72.88M-$23.48M-$85.74M$33.17M-$186.88M-$296.06M-$56.96M-$90.74M$2.78M$10.45M
Financing cash flow-$43.37M$8.37M$4.11M$16.88M$51.93M$314.44M$24.21M$117.18M$40.38M$52.32M
Net change in cash$21.40M$10.37M-$113.65M$101.34M-$23.43M$43.44M$9.35M$18.13M-$22.98M$1.59M
Stock-based compensation$92.38M$101.38M$88.08M$84.92M$60.75M$58.43M$58.07M$23.74M$12.63M$11.66M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchases$0$30.00M$0$0UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$17.67M$16.61M$15.72M$14.33M$13.84M$10.45M$6.07M$5.82M$6.87M$5.49M

Derived

TANDEM DIABETES CARE INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Free cash flow-$29.67M$4.99M-$58.61M$16.37M$97.18M-$2.74M$22.36M-$11.30M-$71.85M-$70.10M
Gross margin53.8%52.1%49.2%51.5%53.5%52.2%53.6%48.9%41.0%28.0%
Operating margin-18.5%-10.5%-31.2%-11.6%3.2%-1.6%-4.6%-24.3%-58.5%-92.6%
FCF margin-2.9%0.5%-7.8%2.0%13.8%-0.5%6.2%-6.1%-66.8%-83.2%
SBC / revenue9.1%10.8%11.8%10.6%8.6%11.7%16.0%12.9%11.7%13.8%
Current ratio2.55x2.93x3.83x5.14x6.15x6.14x2.78x2.83x1.78x2.93x
Revenue YoY growth7.9%25.7%-6.7%14.0%40.9%37.7%97.0%70.9%27.7%Unavailable
Net margin-20.2%-10.2%-29.8%-11.8%2.2%-6.9%-6.8%-66.7%-67.9%-99.0%
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable12.5%15.9%19.2%22.3%
CapEx / revenue2.0%2.0%3.6%4.3%2.0%5.5%5.4%1.6%5.3%10.6%
Long-term debt / equity2.00xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailable2.1%UnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open TNDM in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-19View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-06View SEC filing
10-Q · Filed 2025-04-30View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.